TY - JOUR
T1 - Antiangiogenic drugs for colorectal cancer
T2 - Exploring new possibilities
AU - Ferrarotto, Renata
AU - Hoff, Paulo M.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2013/3
Y1 - 2013/3
N2 - Angiogenesis is essential to cancer development and progression, and its inhibition has been shown to benefit patients with several different malignancies. A considerable number of antiangiogenic compounds have been evaluated for the treatment of colorectal cancer, but only bevacizumab and aflibercept were able to demonstrate a survival benefit in phase III trials. In this review, we discuss important aspects of the interrelationship between tumor cells and the microenvironment leading to tumor progression, with a focus on angiogenesis. Clinical data on antiangiogenic therapies for colorectal cancer in the metastatic and adjuvant settings, as well as the potential use of antiangiogenics beyond tumor progression are analyzed. The need to identify surrogate biomarkers towards a more personalized approach in oncology is emphasized as this is becoming increasingly important in drug development.
AB - Angiogenesis is essential to cancer development and progression, and its inhibition has been shown to benefit patients with several different malignancies. A considerable number of antiangiogenic compounds have been evaluated for the treatment of colorectal cancer, but only bevacizumab and aflibercept were able to demonstrate a survival benefit in phase III trials. In this review, we discuss important aspects of the interrelationship between tumor cells and the microenvironment leading to tumor progression, with a focus on angiogenesis. Clinical data on antiangiogenic therapies for colorectal cancer in the metastatic and adjuvant settings, as well as the potential use of antiangiogenics beyond tumor progression are analyzed. The need to identify surrogate biomarkers towards a more personalized approach in oncology is emphasized as this is becoming increasingly important in drug development.
KW - Aflibercept
KW - Bevacizumab
KW - Cediranib
KW - Metastatic colorectal cancer
KW - Vatalanib
UR - http://www.scopus.com/inward/record.url?scp=84874677879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874677879&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2012.06.002
DO - 10.1016/j.clcc.2012.06.002
M3 - Review article
C2 - 22763196
AN - SCOPUS:84874677879
SN - 1533-0028
VL - 12
SP - 1
EP - 7
JO - Clinical colorectal cancer
JF - Clinical colorectal cancer
IS - 1
ER -